Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Simon Lowry"'
Autor:
Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan M. Mendelsohn, Simon Lowry, Steve Feldman, Jashin J. Wu, April W. Armstrong
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 2, Pp 740-748 (2022)
Objective To evaluate the relative cost-effectiveness of tildrakizumab and other biologic and targeted systemic treatments compared with a mix of topical therapies, phototherapies, and other conventional systemic therapies as first-line treatment for
Externí odkaz:
https://doaj.org/article/21901d76c2a64dcca55ad32c10bf2866
Autor:
Jashin J. Wu, Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan Mendelsohn, Simon Lowry, Steven R. Feldman, April Armstrong
Publikováno v:
Journal of Dermatological Treatment, Vol 32, Iss 7, Pp 693-700 (2021)
Objectives To compare the cost-effectiveness of tildrakizumab with other commonly used biologics and apremilast as the first-line treatment for moderate-to-severe plaque psoriasis from a US health plan’s perspective. Methods A 10-year cost-effectiv
Externí odkaz:
https://doaj.org/article/071f48385fc74c25b671573960db0f0b
Autor:
Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan M. Mendelsohn, Jeffrey Parno, Kenneth Gordon
Publikováno v:
Journal of Dermatological Treatment, Vol 31, Iss 8, Pp 763-768 (2020)
Background: Tildrakizumab is a high-affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody approved for moderate-to-severe plaque psoriasis. Objectives: This analysis examined whether tildrakizumab’s week-28 efficacy can be sustained
Externí odkaz:
https://doaj.org/article/84c339470f9543d89cc146be5b10a8c5
Publikováno v:
Reflective Practice. 24:137-152
Autor:
Maria C. Schutte, Leslie Hebb, Simon Lowry, John Wisniewski, Suzanne L. Hawley, Suvrath Mahadevan, Brett M. Morris, Paul Robertson, Graeme Rohn, Gudmundur Stefansson
Understanding magnetic activity on the surface of stars other than the Sun is important for exoplanet analyses to properly characterize an exoplanet's atmosphere and to further characterize stellar activity on a wide range of stars. Modeling stellar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e1397ee06cd4f943679ebe2d074fbc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alan M. Mendelsohn, Yang Zhao, Simon Lowry, Alan Menter, Jeffrey J. Crowley, Stephen J. Rozzo, J. Parno, Stephen K. Tyring, Boni E. Elewski, Kenneth B. Gordon
Publikováno v:
Journal of Dermatological Treatment. 31:763-768
Background: Tildrakizumab is a high-affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody approved for moderate-to-severe plaque psoriasis.Objectives: This analysis examined whether ...
Autor:
David Huang, Arnold S. Bayer, Yan Q. Xiong, Katyna Borroto-Esoda, Nancy Kerzee, Wessam Abdelhady, Eric Gaukel, Simon Lowry
MRSA endovascular infections are frequently recalcitrant to treatment with standard-of-care antibiotics. Anti-staphylococcal phage lysins represent important candidate adjunctive agents against invasive MRSA infections because of both their microbici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c96b53ea0beb27ae4c5993755596d23c
https://doi.org/10.1101/2021.03.12.435219
https://doi.org/10.1101/2021.03.12.435219
Autor:
Yang Zhao, Thor-Henrik Brodtkorb, Justin Carrico, Alan M. Mendelsohn, Steven R. Feldman, Simon Lowry, Xiaoying Jia, April W. Armstrong, Jashin J. Wu
Publikováno v:
The Journal of dermatological treatment. 32(7)
To compare the cost-effectiveness of tildrakizumab with other commonly used biologics and apremilast as the first-line treatment for moderate-to-severe plaque psoriasis from a US health plan's perspective.A 10-year cost-effectiveness model was develo
Autor:
Xiaoying Jia, Yang Zhao, Thor-Henrik Brodtkorb, Justin Carrico, Simon Lowry, Alan M. Mendelsohn
Publikováno v:
PharmacoEconomics Open
Objective The aim of this study was to evaluate the budget impact of introducing tildrakizumab for moderate-to-severe plaque psoriasis from a US health plan perspective. Methods A budget impact model estimated costs before and after the adoption of t